---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-032885"
form_type: "8-K"
ticker: "SSKN"
cik: "0001051514"
company_name: "STRATA Skin Sciences, Inc."
filed_at: "2024-07-11T23:59:59+00:00"
generated_at: "2026-05-31T21:40:14.082632+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# STRATA pre-announces Q2 revenue $8.0M-$8.4M; XTRAC base down, TheraClear X up

## Summary
- Preliminary Q2 2024 total revenue range: $8.0M - $8.4M.
- Domestic XTRAC installed base fell from 907 (Q1) to 881 (Q2) per device realignment.
- TheraClear X installed base grew from 104 (Q1) to 117 (Q2).
- Cash, cash equivalents, and restricted cash totaled $6.8M at quarter end.
- Full Q2 2024 results expected to be reported on August 14, 2024.

## SEC filing metadata
- accession: 0001140361-24-032885
- form_type: 8-K
- ticker: SSKN
- cik: 0001051514
- company_name: STRATA Skin Sciences, Inc.
- filed_at: 2024-07-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1051514/000114036124032885/0001140361-24-032885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1051514/000114036124032885/ef20032281_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-032885
- JSON: https://secwatch.observer/filing/0001140361-24-032885.json
- Plain text: https://secwatch.observer/filing/0001140361-24-032885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.